The global   ligase market   is projected to reach $651.4 million by 2032 from $371.2 million in 2021, at a CAGR of 5.29% during the forecast period 2022-2032. The growth in the global ligase market is expected to be driven by factors such as the increasing prevalence of infectious and genetic diseases on a global level, rising awareness of enzyme based diagnostic testing and significant number of funding for executing research and development.

Recent Developments in Global Ligase Market

In January 2022, ArcticZymes Technologies launched new products such as ArcticZymes R2DTM Ligase, IsoPol BST+ High Concentration Glycerol FREE and M-SAN HQ ELISA Kit and M-SAN HQ
In April 2022, Codexis, Inc. and Molecular Assemblies, Inc., partnered to engineer enzymes and deliver differentiated and cost-effective solutions for the enzymatic synthesis of DNA.
In May 2022, QIAGEN acquired majority stake of 96% in BLIRT eu., a manufacturer of recombinant enzymes for the life science industry based in Gdansk, Poland. The acquisition was carried out to bring companies capabilities to create additional growth prospects to their enzymes and reagents business.
In July 2021, Merck invested $282.5 million at its global headquarters in Darmstadt. Company is involved in building a new translational science center for its healthcare business sector as well as a new learning center. 

Demand Drivers and Limitations

Following are the demand drivers for the global ligase market:

    Growing Need for Ligases in Disease Treatment 
    Rising Incidence of Diseases such as Cancer and Genetic Disorders
    Rising Focus of Researchers on Non-Toxic Biocatalyst

The market is expected to face some limitations too due to the following challenges:

    High Reception Costs Involving Small and Medium Enterprises
    Variation in the Ability of Ligase to Repair

Key Market Players and Competition Synopsis

The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.

Some of the prominent names established in this market are:

Agilent Technologies, Inc.
ArcticZymes Technologies ASA
BD
Bio-Rad Laboratories, Inc.
Codexis, Inc.
F. Hoffmann-La Roche Ltd.
Merck KGaA
New England Biolabs (UK) Ltd.
Promega Corporation
QIAGEN NV
SBS Genetech
Takara Bio Inc.
Thermo Fisher Scientific, Inc.

Key Questions Answered in the Report

• How is ligase enzyme revolutionizing the field of enzyme-based diagnostics?
• What are the major market drivers, challenges, and opportunities in the global ligase market?
• What are the underlying structures resulting in the emerging trends within the global ligase market?
• How did the COVID-19 pandemic impact the global ligase market?
• What are the key development strategies that are being implemented by the major players in order to sustain themselves in the competitive market?
• What are the key regulatory implications in developed and developing regions pertaining to the use of ligase enzymes?
• What are the potential entry barriers that are expected to be faced by the companies willing to enter a particular region?
• How is each segment of the market expected to grow during the forecast period 2022-2032, and what is the anticipated revenue to be generated by each of the segments?
• What are the growth opportunities for ligase enzyme-providing companies in the region of their operation?
• Who are the leading players with significant offerings in the global ligase market?
• Which companies are anticipated to be highly disruptive in the future, and why?

 The report scope exclusively covers companies that are actively involved in the production of ligase-based products (enzymes) globally. The study considers enzymes and kits based on various underlying applications in chronic diseases to detect biomarkers. 

BIS Research Related Market Studies:

Global Enzymes Market